Fenwick Represents Formation Bio in its Licensing Agreement with Sanofi

Fenwick represented Formation Bio, an AI-native drug development company, in its licensing agreement with Sanofi, a French multinational pharmaceutical and healthcare company.

Formation Bio is developing gusacitinib, a small-molecule drug, for chronic hand eczema. Sanofi will chart a new path for gusacitinib and explore its potential in a new indication that was not previously studied, running a Phase I trial. Additional information can be obtained here.

Fenwick has served as outside counsel to Formation Bio since 2016, led by corporate partner Michael Esquivel. 

The Fenwick transaction team was led by Life Sciences transactions partners Stefano Quintini and counsel Amy Manning, and included associates Pinar Bailey and Nick Zakari.